Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
AssigneeCrispr Therapeutics AG
InventorsMary-Lee Dequeant, Heidi Heath, Rachel Yuen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods, compositions and kits for treating conditions that are related to the modulation of expression of 5′-Aminolevulinate Synthase 1 (ALAS1) by gene editing.
Claims30
A guide RNA (gRNA) for targeting a 5′-Aminolevulinate Synthase 1 (ALAS1) genomic locus, comprising a spacer sequence having 80% sequence identity to any one of the sequences of SEQ ID NOs:
- 25-48 and 83-112.
(canceled)
(canceled)
(canceled)
(canceled)
A composition, comprising:
- (a) a guide RNA (gRNA) that targets a 5′-Aminolevulinate Synthase 1 (ALAS1) genomic locus, or a nucleic acid encoding the gRNA;
- and
- (b) an endonuclease or a nucleic acid encoding an endonuclease.
(canceled)
(canceled)
(canceled)
A method for treating a disease or disorder caused by 5′-Aminolevulinate Synthase 1 (ALAS1) over-expression in a subject in need thereof, comprising administering to the subject a composition comprising a plurality of nanoparticles complexed with:
- (a) a guide RNA (gRNA) that targets a 5′-Aminolevulinate Synthase 1 (ALAS1) genomic locus or a nucleic acid encoding the gRNA;
- and
- (b) a Cas9 endonuclease or a nucleic acid encoding a Cas9 endonuclease, thereby treating the disease or disorder caused by ALAS1 over-expression in the subject.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.